Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BitUSD 2024 has achieved impressive results, and the cross-chain stablecoin ecosystem continues to lead

BitUSD 2024 has achieved impressive results, and the cross-chain stablecoin ecosystem continues to lead

西格玛学长2025/01/14 02:29
bitSmiley is the first platform on the Bitcoin blockchain to provide native lending and stablecoin integration, encapsulated by its proprietary Fintegra technology, completely changing decentralized finance.
 
On January 13th, bitSmiley Labs announced its major achievements for 2024. BitUSD has made remarkable progress in the stablecoin field.
BitUSD has successfully risen to become the leading decentralized stablecoin in the BTC ecosystem.
Leading cross-chain layout: Expanding to the BTC mainnet and multiple Layer 2 networks, achieving cross-chain coverage of BTC liquidity.
Technology innovation delivery: Launch of PSM and D3M systems to provide unmatched stability for bitUSD.
Strong community growth: With user support, the community continues to grow in size and strength.
bitSmiley Labs stated that 2024 is an important year, and 2025 will continue to drive more breakthroughs
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53